NCT05340634 is a Phase 4 clinical trial of Metionac in Polycystic Ovary Syndrome, sponsored by Margan Biotech.

Who is sponsoring NCT05340634?

NCT05340634 is sponsored by Margan Biotech.

What drugs are being tested in NCT05340634?

Interventions in NCT05340634: Metionac, Oral contraceptive.

What condition does NCT05340634 study?

NCT05340634 studies Polycystic Ovary Syndrome.

Is NCT05340634 still recruiting?

NCT05340634 is currently completed. Last updated 28 April 2022.

Last reviewed 2022-04-28 · How we verify

NCT05340634

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.

Completed Phase 4 Last updated 28 April 2022

What this trial tests

Phase 4 trial testing Metionac in Polycystic Ovary Syndrome in 90 participants. Completed in 2 February 2022.

Timeline

20 April 2020

Primary endpoint
2 February 2022

2 February 2022

Quick facts

Lead sponsor	Margan Biotech
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	20 April 2020
Primary completion	2 February 2022
Estimated completion	2 February 2022
Sites	1 location across Spain

Drugs / interventions tested

Metionac
Oral contraceptive — full drug profile →

Conditions studied

Polycystic Ovary Syndrome — all drugs for Polycystic Ovary Syndrome →

Sponsor

Margan Biotech

Who can join

18 and older, female only, with Polycystic Ovary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the efficacy of the combination of antioxidants ALA, NAC, Vit. B6 and SAMe as a dietary supplement, in the improvement of metabolic and endocrine parameters and clinical manifestations of PCOS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Polycystic Ovary Syndrome

Currently open trials in the same condition.

NCT07591246 — Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction · NA · recruiting
NCT07446985 — Is There a Benefit From Addition of Physical Exercise to Diet Restriction/Limitation in PCOS Women With Asthma? · NA · recruiting
NCT07385716 — Evaluation of the Effect of Time-Restricted Feeding and Mediterranean Diet Model in Women With Polycystic Ovary Syndrome · NA · recruiting
NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
NCT07289399 — Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS? · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05340634 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Margan Biotech
Last refreshed: 28 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05340634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing